Robin Foà , MD from the Sapienza University, Rome, Italy gives an overview of the session on ‘Biosimilars: shaping the future of Hematology’ held at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Prof. Foà discusses how advancements in therapy are impacting on the prognosis of various cancers and, in this context, the problems associated with an aging society. He then talks about drug costs and the issue of access to novel drugs. According to Prof. Foà , biosimilars may help reduce costs and increase access to drugs.
The potential impact of biosimilars in hematology
